Rodents are poor model for human hyperlipidemias because total cholesterol and low density lipoprotein levels are very low on a normal diet. Lipoprotein metabolism is primarily regulated by hepatocytes and we therefore assessed whether chimeric mice extensively repopulated with human cells can model human lipid and bile acid metabolism.
FRG [Fah(−/−)Rag2(−/−)Il2rg(−/−)]) mice were repopulated with primary human hepatocytes. Serum lipoprotein lipid composition and distribution (VLDL, LDL, and HDL) was analyzed by size exclusion chromatography. Bile was analyzed by LC-MS or by GC-MS. RNA expression levels were measured by quantitative RT-PCR.
Chimeric mice displayed increased LDL and VLDL fractions and a lower HDL fraction compared to wild type, thus significantly shifting the ratio of LDL/HDL towards a human profile. Bile acid analysis revealed a human-like pattern with high amounts of cholic acid and deoxycholic acid (DCA). Control mice had only taurine-conjugated bile acids as expcted, but highly repopulated mice had glycine-conjugated cholic acid as found in human bile. RNA levels of human genes involved in bile acid synthesis including CYP7A1, and CYP27A1 were significantly upregulated as compared to human control liver. However, administration of recombinant hFGF19 restored human CYP7A1 levels to normal.
Humanized-liver mice showed a typical human lipoprotein profile with LDL as the predominant lipoprotein fraction even on a normal diet. The bile acid profile confirmed presence of an intact enterohepatic circulation. Although bile acid synthesis was deregulated in this model, this could be fully normalized by FGF19 administration. Taken together these data indicate that chimeric FRG-mice are a useful new model for human lipoprotein and bile-acid metabolism.
Citation: Ellis ECS, Nauglers S, Parini P, Mörk L-M, Jorns C, Zemack H, et al. (2013) Mice with Chimeric Livers Are an Improved Model for Human Lipoprotein Metabolism. PLoS ONE 8(11): e78550. https://doi.org/10.1371/journal.pone.0078550
Editor: Vasu D. Appanna, Laurentian University, Canada
Received: December 6, 2012; Accepted: September 19, 2013; Published: November 4, 2013
Copyright: © 2013 Ellis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Human hepatocytes were obtained from Pittsburgh, PA (to Stephen C. Strom), through the Liver Tissue and Cell Distribution system (N01-DK-7-0004/HHSN267200700004C). This work was supported by grants from the National Institute of Health to Markus Grompe (R01DK05192). The Swedish Research Council, the Swedish Heart-Lung Foundation, the Karolinska Institute to PP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Stephen C. Strom and Markus Grompe own stock in Yecuris Corporation. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
The use of experimental animals in scientific research has enabled some of the most important breakthroughs in medical research . Further refinement of animal models through genetic manipulations is an important and powerful tool in research today. Transplanting human cells and tissues into genetically engineered mice expands these possibilities. Humanized mouse models present opportunities to study whole cellular systems in an in vivo setting , , , .
Mice and human differ greatly in many aspects of cholesterol metabolism ranging from lipoprotein processing to cholesterol catabolism through bile acid synthesis. In mice, serum cholesterol is found mainly in high-density lipoproteins (HDL), while humans have mainly low-density lipoproteins (LDL). Several of the apolipoproteins synthesized by the liver are different in man and mice, such as ApoB and ApoE, and others such as Lp(a) are absent in mice altogether. Genetically modified mouse strains have been developed for atherosclerosis research, but the information gained has been limited because of the major species differences and the complex nature of cholesterol and lipid metabolism , , . Furthermore catabolism of cholesterol via bile acid synthesis differs in mice and humans. Mice have an additional bile acid, muricholic acid, not present in humans, with beta-muricholic acid as the major form. It is well known that the different bile acids regulate overall bile acid synthesis differently in different species . Regulation of the rate limiting enzyme in bile acids synthesis, cholesterol 7alpha-hydroxylase is dissimilar, and frequently opposite in rodents and man . The murine promoter of this gene has a response element for LXR which is not present in humans . Thus, stimulation of LXR by cholesterol leads to a feed-forward regulation that increases the synthesis of bile acids in mice, but not in humans.
Endocrine signaling between intestine and liver differ in man and mice. Humans secrete fibroblast growth factor 19 (FGF19) in response to increases in the ileal bile acid pool that results in a down-regulation of hepatic CYP7A1, the rate-limiting enzyme in bile acid synthesis. In contrast, mouse intestine signals through FGF15 , .
There are also species differences in conjugation of bile acids. Humans can amidate bile acids with both glycine and taurine , with a preference for glycine in adulthood. Mice conjugate almost exclusively with taurine .
Given the number of differences between mouse and human cholesterol and bile acid regulation and profiles, and considering that the liver is the major organ involved in the synthesis of these proteins, a mouse model with livers repopulated with human hepatocytes offers a useful model to investigate these pathways, in vivo. The aims of this study were to determine whether cholesterol and bile acid metabolism in FRG mice repopulated with human hepatocytes displayed a characteristic human profile, composition and regulation.
Human liver tissue and hepatocytes were obtained through the Liver Tissue Cell Distribution System, and the studies were exempted by IRB 0411142 since no human subjects were involved (University of Pittsburgh). All animal work was conducted according to approved Institutional Animal Care and Use Committee (IACUC, Yecuris) protocol DN000024 and NIH OLAW assurance #A4664-01. The protocols follow the NIH guidelines for laboratory animal use and welfare.
Transplantation of FRG mice
FRG mice were maintained as described previously . Mice are maintained on NTBC (Nitisinone, Swedish Orphan International, Stockholm) in the drinking water (16 mg/l). Mice are injected, IP, 24 hr prior to transplant with 109pfu of an adenoviral vector expressing the secreted form of uPA and receive up to 1 million human hepatocytes in 100 microliters of DMEM media via splenic injection. Following transplant, NTBC is gradually withdrawn to initiate loss of native hepatocytes. Progress of humanization is monitored monthly blood analysis by ELISA assay for human serum albumin (hSA). In general 1 mg/ml of circulating hSA correlates with ∼20% engraftment of human cells, 2 mg with ∼40%, and animals with 4 mg are approximately 80% repopulated. Hepatocytes were obtained from the Liver Tissue and Cell Distribution System, University of Pittsburgh or commercially available sources. Human hepatocytes (fresh and from serial transplantation) were cold-stored in University of Wisconsin solution for up to 48 hours, allowing additional time for transplants. Serial transplants were conducted as described previously . At the time of serial transplantation, an aliquot of the cells were used for RNA isolation and the rest for transplantation.
At sacrifice, liver tissues was collected and snap frozen in liquid nitrogen for RNA expression analysis, serum was collected for measurement of lipoproteins and bile acid intermediates and gallbladder bile was collected for bile acid analysis.
Cholesterol content of serum lipoproteins was separated by size exclusion chromatography from mouse or human serum and was measured according to Parini et al .
Western blotting of mouse and human Apo E
Serum samples were separated by electrophoresis on 10% Bis-TrisNuPAGE Gel (Invitrogen). Proteins were transferred to a nitrocellulose membrane (Invitrogen) and incubated with rabbit anti human ApoE (Gene Tex GTX 101456) or rabbit anti mouse ApoE (Pierce PAI-46367). Donkey anti-rabbit HRP-conjugated IgG (GE Healthcare) was used as the secondary antibody. Signal was detected using the ECL kit according to instructions (Thermo Scientific).
GC-MS analysis of bile acids in bile
Bile acids were analyzed as previously described by Björkhem et al  and Ellis et al.. Briefly, 10 ul of gallbladder bile was diluted with 1 ml of water, 2 ml of 50% EtOH, 1g KOH and hydrolyzed together with 2500 ng deuterium labeled Cholic acid (D5) and chenodeoxycholic acid (D4), Deoxycholic acid (D4), Ursodeoxycholic acid (D4) at 125° C over night. Samples were diluted with saline and extracted twice with ether to remove neutral steroids. Following acidification with HCl (6M) to pH 1, bile acids were extracted with ether. The ether phase was methylated with trimethylsilyldiazomethane (Sigma cat.:36,283-2) and silylated using hexamethyl-disilazane (Alfa Aesar L16519) and trimethylchlorosilane (Merck 1.02333.0100) in pyridine at 60° C for 30 minutes. Solvent was evaporated and the samples dissolved in 200 ul of Hexane and analyzed by GC-MS (Agilent 5973 6890N). Data were analyzed using Agilent Mass hunter software.
LC-MS/MS analysis of bile acid conjugates in bile
Bile acids were analyzed using HPLC-MSMS using a modified method initially described by D Tagliacozzi et al. . Two ul of bile was mixed with 800ng internal standards in 40 µl methanol and 800 ul acetonitrile. The mixture was centrifuged at 13 000 x g for 15 minutes and the upper phase was transferred to a disposable glass centrifuge tube and evaporated under N2. Residue was dissolved in 75 ul of Methanol, vortexed and transferred to Waters vials. Tubes were rinsed with 75 ul 40% Methanol in water, 0.02% Formic acid and 10 mM Ammonium acetate and pooled. A Waters LC-MS/MS MicromassQuattro Micro, equipped with a C18 reverse- phase column and ESI in negative mode was used for analysis.
Six different deuterium labeled internal standards (D5-CA, D4-UDCA, D4-LCA, D4- GCA, D4-GUDCA, D4-GLCA), and unlabeled unconjugated bile acids (LCA, DCA, CDCA, HDCA, UDCA, CA, HCA, BMCA, AMCA and OMCA) and glycine- as well as taurine- conjugated bile acids (GLCA, GDCA, GCDCA, GCA, GUDCA, TLCA, TDCA, TCDCA, TCA, TUDCA) were used for calibration and quantification.
Unconjugated bile acids were measured by molecular anions (no product ions are produced). Glycine- or taurine-conjugated bile acids were quantified from negative daughter ions, generated after loss of the conjugate.
Twelve FRGN mice were used, six were repopulated with human hepatocytes and six were used as controls. When serum human albumin levels indicated the mice were repopulated with human hepatocytes, FGF19 was administered. Recombinant human FGF-19 (PeproTech, Catalog # 100-32) was reconstituted in 0.9% saline with 0.1% BSA and three humanized and three control FRGN mice were injected (s.q.) with 0.5 mg/kg FGF19 twice daily for three days. Three humanized and three control FRGN mice were injected with diluents only. Mice were killed between 1–3 hours after the final injection, after their gallbladders had been cannulated for a 15–20 minute collection of bile. Serum and liver were harvested and snap frozen in liquid nitrogen.
RNA was extracted using Trizol (Invitrogen cat#: 15596-026). Integrity was checked on a 1% agarose gel with 1xTAE and concentration measured using the Nano Drop (ND-1000) spectrophotometer.
A high capacity cDNA reverse transcription kit from Applied Biosystems cat# 4374966 with RNAse inhibitor was used according to instructions.
RNA expression was quantified using real time PCR (ABI prism 7000). For human genes predesigned Taqman probes were used. hCyp8B1: Hs00244754_s1, hCyp27A1: Hs00168003_m1, hCyp7A1: Hs00167982_m1, hCyc (PPIA): Hs99999904_m1, hSHP: Hs00222677_m1, hFGF19: Hs 00192780_m1, hABCB11: HS00184824_m1, hNTCP: HS00161820_m1, hFXR: Hs00231968_m1.
For mouse genes the SYBR Green method was used with the following primer sequences;mCyclophilinFw: GAT-GAG-AAC-TTC-ATC-CTA-AAG-CAT-ACA, mCyclophilin Rev: TCA-GTC-TTG-GCA-GTG-CAG-ATA-AA, mCYP7A1 Fw: AGC—AAC-TAA-ACA-ACC-TGC-CAG-TAC-TA, mCYP7A1 Rev: GTC-CGG-ATA-TTC-AAG-GAT-GCA, mGAPDHFw: TGT-GTC-CGT-CGT-GGA-TCT-GA, mGAPDH Rev: CCT-GCT-TCA-CCA-CCT-TCT-TGA-T, mABCG5 Fw: TGG-ATC-CAA-CAC-CTC-TAT-GCT-AAA, mABCG5 Rev: GGC-AGG-TTT-TCT-CGA-TGA–ACT-G, mABCG8 Fw: TGC-CCA-CCT-TCC-ACA-TGT-C, mABCG8 Rev: ATG-AAG-CCG-GCA-GTA-AGG-TAG-A, mSHP-Fw: AAG-GGC-ACG-ATC-CTC-TTC-AA, mSHP-Rev: CTG-TTG-CAG-GTG-TGC-GAT-GT
Serum Lipoprotein profiles
Cholesterol metabolism involves complex interplays between absorption, production and excretion. In mice, serum cholesterol is found mainly as high-density lipoproteins (HDL), while in man, low density lipoproteins (LDL) predominate. Since lipoprotein synthesis is a hepatic function, in mice with livers repopulated with human hepatocytes, one could expect serum lipoproteins to change from a HDL to an LDL centered profile. Cholesterol lipoprotein profiles were measured in serum of wild type, non-repopulated and repopulated mice as well as a human control sample, figure 1A. Data presented in figure 1B shows the cholesterol content of different lipoprotein fractions. In wild type and non-repopulated FRG mice HDL is the predominant lipoprotein constituent. In human serum samples and in FRG mice repopulated with human hepatocytes, HDL was decreased while LDL was increased from a ratio of LDL/HDL of approximately 0.3 in non-repopulated animals to 0.9, 1.0, 1.5 in mice repopulated to 45, 88 or 90%, respectively, approaching the value of 1.6 from a healthy 38 year old female.
A, Serum cholesterol lipoprotein profiles measured by size exclusion chromatography of wild type mice, human, high (90%) and low (45%) levels of repopulation in humanized FRG mice. Panel B showing percentage of different lipoprotein fractions, as well as ratio of LDL/HDL in wild type mice, human controls, repopulated FRG mice and FRG controls. C, Western blot analysis of human (h) and mouse (m) Apolipoprotein E in serum samples of human and mouse control samples, 1–6. Humanized FRG with different levels of repopulation are shown in lane 7–9.
Apolipoprotein E is synthesized by hepatocytes and also binds to hepatic receptors as part of the catabolic pathway for triglyceride-rich lipoproteins. Western blot analysis, shown in figure 1C, revealed that FRG mice repopulated with human hepatocytes synthesize and secrete human and mouse ApoE.
Bile acid conjugates
Bile acids are conjugated in hepatocytes prior to excretion into bile. The conjugation of bile acids differs significantly between species; mice conjugate almost exclusively with taurine whereas humans conjugate with both glycine and taurine at a ratio of approximately 5:1. In mice repopulated with human hepatocytes one could expect to find glycine conjugated bile acids. Bile acids conjugates were analyzed in mouse bile using LC-MS/MS. Table 1 shows the percentages of taurine conjugated cholic acid (T-CA), glycine conjugate cholic acid (G-CA) and unconjugated cholic acid (CA) in humanized and control mice. The results showed that in highly repopulated mice (88–94% humanized) the proportion of T-CA was decreased and both free CA and G-CA increased relative to FRG controls.
Bile acid composition
Bile acid composition in mice differs from humans by the presence of additional bile acids in mice, alpha, beta and omega- muricholic acid, with beta as the major form. In rodents bile acids that have been de-hydroxylated in the intestine producing the secondary bile acid deoxycholic acid (DCA) can be re-hydroxylated to cholic acid. Humans do not re-hydroxylate and therefore have higher levels of secondary bile acids such as DCA. Following hydrolysis, we extracted bile acids from 1 ul of bile and analyzed them by GC-MS. Table 2 shows percentage of individual bile acids and the ratio of DCA to beta-muricholic acid (BMCA). As shown in figure 2A, the ratio of DCA/BMCA from non-transplanted mice was significantly different in highly repopulated < 80%, (p = 0.063) and moderately repopulated mice (50–80%, p = 0.026). In mice with a low degree of repopulation (30-50%), the ratio of DCA/BMCA was not significantly different from non-transplanted animals.
A, Ratio of deoxycholic acid (DCA) over beta-muricholic acid (BMCA) in high (<80%), moderate (50–80%) or low (30–50%) population compared to non-transplanted FRG mice. Statistics were performed by a 1-way ANOVA on log-transformed data followed by Dunett’s test. The overall significance was p = 0.023 (all different vs control). B, RNA expression of CYP7A1, CYP8B1 and CYP27A1 in hepatocytes, normalized to cyclophillin analyzed by quantitative real time PCR. Expression of human genes were analyzed in hepatocytes isolated from humanized FRG (Tx-Mice) and compared to isolated human hepatocyte controls (Human). Statistics were performed by a non-parametric Mann-Whitney U test.
RNA expression in humanized mice
Expression of the rate limiting enzyme in the bile acid synthesis Cholesterol 7alfa-hydroxylase, CYP7A1, revealed a significant (p<0.05) increase from 0.008 (arbitrary value) in humans (n = 5) to 0.473 in humanized mice. This reflects a∼57-fold of CYP7A1 increase in humanized mice (figure 2B).
The expression of Sterol 27-hydroxylase(CYP27A1), the enzyme responsible the first step in the side chain degradation and the first step of the acidic pathway of bile acid synthesis, was also significantly increased from 0.5 (arbitrary value) in humans (n = 5) to 1.8 in humanized mice (n = 3), p<0.05 (figure 2B).
The expression of Sterol 12α-hydroxylase (CYP8B1), the enzyme responsible for formation of cholic acid (and subsequently deoxycholic acid), was not significantly different in humanized mice (0.58) compared to human controls (0.52) (figure 2B).
Administration of FGF19
We hypothesized that the 57-fold increase in CYP7A1was due to a mismatch in signaling between the murine intestine and human hepatocytes. We injected recombinant human FGF19, 0.5 mg/kg body weight, subcutaneously (s.q.) twice daily for 3 days into humanized (TxFRG) mice or non-humanized FRG controls. The experiment was terminated 5 hrs after the last injection, bile was collected over a 15 minute period and the liver snap frozen for RNA expression analysis.
Administration of FGF19 lead to a significant decrease of the total bile acid concentration in bile of humanized mice, from 24 500 ng/ul to 9 000 ng/ul, p = 0.001 (table 3). Non-transplanted mice injected with FGF19 also exhibited the same effect decreasing from 17 300 ng/ul to 9 450 ng/ul after infusion (p = 0.01), table 3.
Expression of human CYP7A1 was significantly (∼ 80-fold) decreased in humanized mice treated with FGF19 compared to controls, from 2.58 (arbitrary value) in transplanted FRGN, to 0.032 following FGF19 injection (p = 0.061). The expression of CYP7A1 was not significantly different between FGF19 treated FRG mice and human controls, figure 3A.
A, Expression of human CYP7A1 in humanized FRG mice (TxFRG) treated with FGF19 (TxFRG+FGF19) compared to human control. Statistics were performed by a non-parametric Kruskal-Wallis ANOVA. The overall significance of the experiment was p<0.05. Expression of human CYP8B1 (B), CYP27A1(C), FXR (D) and SHP (E) in livers of humanized mice (TxFRG) treated with FGF19 (TxFRG+FGF19). Human liver RNA was used for reference (n = 9).
RNA expression of hCYP8B1, hCYP27A1 and the nuclear receptors, short heterodimer partner, SHP and farnesoid x receptor protein, FXR are shown in figure 3B-E. Expression of hCYP8B1,hCYP27A1 and hFXR were not altered by administration of FGF19, however hSHP was significantly decreased (p<0.05),figure 3E. Administration of FGF19 significantly decreased mouse Cyp7a1 (p = 0.001) expression in both humanized and non-transplanted FRG mice (n = 3) as expected (figure 4A). Expression of mCyp8b1 and mCyp27a1 were also significantly decreased by FGF19 injection whereas mouse SHP did not decrease in humanized mice, but significantly (p<0.001) decreased in the non-transplanted mice (figure 4B-D).
A, Cyp7a1, B,Cyp27a1, C, Cyp8b1, and E, SHP in livers of both FRG and humanized FRGN mice (TxFRG), with or without FGF19 (TxFRG+FGF19, FRG+FGF19). Statistics were performed by a 1-way ANOVA on log-transformed data followed by LSD test.
The lack of a small animal model of hepatic lipoprotein metabolism has limited research in this important area of biomedicine. Rodent and humans have cardinal differences in cholesterol metabolism and lipoprotein profiles that protect rodents from atherosclerosis. One of the major differences is the ratio of LDL and HDL and the cholesterol levels. Mice have lower levels of total cholesterol, and the major lipoprotein is HDL.
In this study we attempt to recreate human lipoprotein and bile acid metabolism in mice using FRG mice transplanted with human hepatocytes. Chimeric mice highly repopulated with human hepatocytes showed a shift from a HDL phenotype to a LDL centric distribution of lipoproteins. Mice with highly humanized livers showed lipoprotein profiles nearly identical to human plasma samples. Hence this mouse model will be an important tool to test the effects of drugs and gene therapy on the synthesis, secretion and uptake of human lipoproteins by hepatocytes. Moreover, in contrast to humans, rodents fed a high-cholesterol diet are resistant to the development of hypercholesterolemia , . With the changes in lipoprotein levels observed in repopulated FRG animals, these mice may be sensitive to dietary cholesterol challenges. Additional studies are needed to test this hypothesis. Another important feature of the model presented here is the expression of human apolipoproteins, such as Apo E. Not only could we detect human Apo E (figure 1C), we could also discriminate different protein isoforms (not shown) from different cell donors. This is important because different phenotypes are associated with certain characteristics, for example ApoE2/2 is associated with type 3 dyslipidemia.
Bile acid amidation differs between species; mice conjugate almost exclusively with taurine whereas humans conjugate with both glycine and taurine at a ratio of approximately 5:1. We expected the conjugation pattern to be altered in humanized mice and we did see the appearance of glycine-conjugated bile acids in highly repopulated mice. The highest degree of glycine conjugation was on cholic acid (table 1). Unexpectedly we observed up to 11% unconjugated cholic acid in bile. This is puzzling, as the non-transplanted mice do not have much free cholic acid in bile. Free biliary bile acids, mainly cholic acid, have been described in rats (10–15%) and the possum. It is unusual to find free bile acids in bile of humans. Matoba et al reported that 0.1–0.4% of bile acids in bile were unconjugated, but these were mainly unusual C23 and C27 bile acids . The occurrence of free cholic acid in highly repopulated mice observed here could simply be due a hepatic depletion of taurine. This hypothesis will be tested in future experiments by supplementation of dietary taurine.
We hypothesized that repopulation with human hepatocytes would also significantly alter bile acid composition. Table 2 shows the percentage of individual bile acids as well as the level of humanization and human serum albumin levels. The percentage of beta - muricholic acid (BMCA) is slightly lower in repopulated mice compared to non-transplanted FRG mice. Deoxycholic acid (DCA) also increased in humanized mice as expected, and the ratio of DCA/BMCA was significantly higher in both highly and moderately repopulated mice. It is somewhat surprising that high levels of repopulation (>80%) did not give a more completely humanized bile acid composition. This may be explained by the higher synthesis rate of bile acids in mice. Healthy humans synthesize about 500 mg of bile per day , which corresponds to about 0.35 mg per gram of liver. Mice synthesize 4.3 mg per day per 100 grams of body weight, which corresponds to about 0.78 mg of bile per day per gram liver , . This rate is twice of that observed in humans and may contribute to the murine composition as would the ability of rodent hepatocytes to rapidly transform CDCA, DCA and CA into beta-muricholic acid .
The regulation of bile acid synthesis involves a complex series of events involving both the liver and intestines. Hepatic bile acid synthesis is feedback inhibited by bile acids returning to the liver via enterohepatic circulation. Thus, bile acid synthesis is stimulated if bile acids are constantly removed (via fistula) or inhibited by normal enterohepatic recirculation of bile acids or as in the case of drug therapy, where taurine conjugated bile acids are introduced into the intestines. A humanized mouse model offers a unique opportunity to examine the regulation of human CYP7A1 and bile acids production in vivo and to investigate feedback signaling between the intestines and liver. In mice, FGF15, and in humans, FGF19, is thought to be released from intestines when bile acid pools are sufficient to inhibit the expression of CYP7A1, the rate-limiting step in bile acid synthesis in hepatocytes. We observe a 57-fold increase in the RNA levels of the rate-limiting enzyme CYP7A1 in human hepatocytes in humanized mice as compared to normal human hepatocytes. We speculate that this is due to abnormal FGF signaling between murine intestine and human liver cells. Therefore, FGF19 was administered (s.q) in single or repeated injections and human (h) CYP7A expression and bile acids production was examined. As expected, FGF19 injection was sensed by the human hepatocytes and led to a dramatic decrease in both hCYP7A expression and bile acid production in the animals, confirming the hypothesis that lack of FGF19 lead to an increased hCYP7A expression and bile acid production. The positive response in human hepatocytes to FGF19 administration confirms that the human hepatocytes within the mouse liver respond to the species appropriate FGF with the expected outcome of suppression of CYP7A and bile acid production. This humanized FRG model offers a unique opportunity to examine human relevant modulation of bile acid production, in vivo.
The bile acid concentration in gallbladder bile was reduced following injection of FGF19 in both repopulated and control mice. The concentration of DCA was lower following injection of FGF19 in humanized mice whereas omega muricholic acid increased following administration in non-transplanted FRG mice. In repopulated mice injection of FGF19 leads to repression and a normalization of hCYP7A1. hCYP8B1 was also repressed whereas hCYP27A1 was not altered. However, hSHP expression did not increase following FGF19 injection, in fact it decreased. Holt et al.  suggested that FGF19 represses CYP7A1 through a SHP independent mechanism. We previously reported that treatment with bile acids or FGF19 substantially increased SHP protein stability in cultured human hepatocytes or mice in vivo . Therefore, the role of SHP in the regulation of CYP7A1 by FGF19 remains unclear.
Our studies confirm previous studies that FGF19 down regulates mouse cyp7a1, in both control mice and humanized mice . Interestingly, mouse Shp was down regulated by infusion of FGF19 in FRG controls, but not in repopulated FRG mice, however levels are already low in the repopulated mice and there was no further down regulation by FGF19 injection. One possible explanation for this could be that human hepatocytes subjected to high levels of bile acids in the FRG mouse express and secrete FGF19 in a paracrine manner and it has been suggested that human hepatocytes may contribute to the circulating FGF19 levels found in humans . However, due to restricted amounts of serum available from these mice, analysis of circulating FGF19 levels could not be completed in the present studies.
In this report we demonstrate that FRG mice repopulated with primary human hepatocytes display a serum lipoprotein profile nearly identical to humans including human apolipoproteins. Gallbladder bile of highly repopulated are altered towards a more human composition including the appearance of glycine conjugated bile acids. Also, increased levels of the secondary bile acid deoxycholic acid show that repopulated mice have a functioning enterohepatic circulation. Taken together, these results demonstrate that repopulated FRG mice have the potential to be a unique small animal model of atherosclerosis and cholesterol metabolism where not only the lipoproteins and bile acids are humanized, but the whole arsenal of functions that liver cells perform, including drug metabolizing enzyme systems. Our experiments with FGF19 injection also illustrate how this unique model can be used to elucidate regulatory pathways and the contributions of different organs to liver homeostasis.
Conceived and designed the experiments: EE SS SN MG PP BGE IB. Performed the experiments: EE SN LMM CJ HZ ALS EMW. Analyzed the data: EE SN PP LMM CJ HZ ALS IB BGE EMW SS MG. Contributed reagents/materials/analysis tools: EE SS BGE MG IB PP CJ. Wrote the paper: EE PP SS MG SN IB BGE.
- 1. Society TR (2004) The Use of non-human animals in research: a guide for scientists. The royal society.
- 2. Strom SC, Davila J, Grompe M (2010) Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640: 491–509.
- 3. Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, et al. (2011) Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25: 223–235.
- 4. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118–130.
- 5. Katoh M, Tateno C, Yoshizato K, Yokoi T (2008) Chimeric mice with humanized liver. Toxicology 246: 9–17.
- 6. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, et al..(2011) Animal models of cardiovascular diseases. J Biomed Biotechnol 497841.
- 7. Chen Z, Chu D, Castro-Perez JM, Ni W, Zhang A, et al. (2011) AAV8-Mediated Long-Term Expression of Human LCAT Significantly Improves Lipid Profiles in hCETP;Ldlr(+/-) Mice. . J Cardiovasc Transl Res. 4(6): 801–10.
- 8. de Vries-van der Weij J, Zadelaar S, Toet K, Havekes LM, Kooistra T, et al. (2009) Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis 206: 153–158.
- 9. Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thorne A, et al. (2003) Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38: 930–938.
- 10. Ellis E, Goodwin B, Abrahamsson A, Liddle C, Mode A, et al. (1998) Bile acid synthesis in primary cultures of rat and human hepatocytes. Hepatology 27: 615–620.
- 11. Chiang JY, Kimmel R, Stroup D (2001) Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262: 257–265.
- 12. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217–225.
- 13. Lundasen T, Galman C, Angelin B, Rudling M (2006) Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260: 530–536.
- 14. Sjovall J (1959) Dietary glycine and taurine on bile acid conjugation in man; bile acids and steroids 75. Proc Soc Exp Biol Med 100: 676–678.
- 15. Inoue Y, Yu AM, Inoue J, Gonzalez FJ (2004) Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J Biol Chem 279: 2480–2489.
- 16. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, et al. (2007) Robust expansion of human hepatocytes in Fah–/–/Rag2–/–/Il2rg–/– mice. Nat Biotechnol 25: 903–910.
- 17. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M (2006) Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 36: 98–104.
- 18. Bjorkhem I, Falk O (1983) Assay of the major bile acids in serum by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 43: 163–170.
- 19. Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, et al. (2003) Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med 41: 1633–1641.
- 20. Bjorkhem I, Lund E, Rudling M (1997) Coordinate regulation of cholesterol 7 alpha-hydroxylase and HMG-CoA reductase in the liver. Subcell Biochem 28: 23–55.
- 21. Russell DW, Setchell KD (1992) Bile acid biosynthesis. Biochemistry 31: 4737–4749.
- 22. Matoba N, Une M, Hoshita T (1986) Identification of unconjugated bile acids in human bile. J Lipid Res 27: 1154–1162.
- 23. Einarsson K, Nilsell K, Leijd B, Angelin B (1985) Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med 313: 277–282.
- 24. Yokoyama HO, Wilson ME, Tsuboi KK, Stowell RE (1953) Regeneration of mouse liver after partial hepatectomy. Cancer Res 13: 80–85.
- 25. Schwarz M, Russell DW, Dietschy JM, Turley SD (1998) Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J Lipid Res 39: 1833–1843.
- 26. Princen HM, Meijer P (1988) Hydroxylation, conjugation and sulfation of bile acids in primary monolayer cultures of rat hepatocytes. Biochem Biophys Res Commun 154: 1114–1121.
- 27. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, et al. (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581–1591.
- 28. Miao J, Xiao Z, Kanamaluru D, Min G, Yau PM, et al. (2009) Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev 23: 986–996.
- 29. Song KH, Li T, Owsley E, Strom S, Chiang JY (2009) Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49: 297–305.